MNPR Presents Phase 3 Neurologic Wilson Disease Data, ALXN1840 Shows 45% Improvement vs 32% SoC, Durable Benefit, Favorable Safety
Monopar Therapeutics Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $64.40
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS